Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Tablet Scoring Guidance Holds Brands, Generics To Single Standard

This article was originally published in The Tan Sheet

Executive Summary

Generic and private label industry concerns that scoring conventions could create barriers to market entry did not win out in the agency’s final tablet scoring guidance. FDA advises firms to contact the agency when questions arise about a product’s scoring being patent-protected.

You may also be interested in...



CMC Review Update: Evenity Sequence Variants, Sunosi Split-Tablet Risks, Mayzent Particle Size

Redacted drug approval packages highlight key issues in US FDA quality reviews of Amgen’s Evenity, Jazz’s Sunosi and Novartis’ Mayzent.

FDA Will Allow 10 Minor ANDA Corrections Before Refusing To Receive

Generic Drug User Fee Act refuse-to-receive draft guidance says FDA will allow sponsors to make a few small fixes to applications, but the agency will not accept any ANDAs with big problems, which will trigger automatic refuse-to-file actions.

FDA Will Allow 10 Minor ANDA Corrections Before Refusing To Receive

Generic Drug User Fee Act refuse-to-receive draft guidance says FDA will allow sponsors to make a few small fixes to applications, but the agency will not accept any ANDAs with big problems, which will trigger automatic refuse-to-file actions.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel